- Home
- CSTL vs TRC Comparison
CSTL vs TRC Comparison
Compare CSTL & TRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- TRC
- Stock Information
- Founded
- CSTL 2007
- TRC 1843
- Country
- CSTL United States
- TRC United States
- Employees
- CSTL N/A
- TRC N/A
- Industry
- CSTL Medical Specialities
- TRC Real Estate
- Sector
- CSTL Health Care
- TRC Finance
- Exchange
- CSTL Nasdaq
- TRC Nasdaq
- Market Cap
- CSTL 456.2M
- TRC 463.5M
- IPO Year
- CSTL 2019
- TRC N/A
- Fundamental
- Price
- CSTL $18.52
- TRC $16.55
- Analyst Decision
- CSTL Strong Buy
- TRC
- Analyst Count
- CSTL 6
- TRC 0
- Target Price
- CSTL $37.67
- TRC N/A
- AVG Volume (30 Days)
- CSTL 419.5K
- TRC 104.4K
- Earning Date
- CSTL 08-04-2025
- TRC 08-05-2025
- Dividend Yield
- CSTL N/A
- TRC N/A
- EPS Growth
- CSTL N/A
- TRC 298.28
- EPS
- CSTL N/A
- TRC 0.08
- Revenue
- CSTL $347,083,000.00
- TRC $42,689,000.00
- Revenue This Year
- CSTL N/A
- TRC $0.64
- Revenue Next Year
- CSTL $1.36
- TRC N/A
- P/E Ratio
- CSTL N/A
- TRC $207.56
- Revenue Growth
- CSTL 38.43
- TRC 7.04
- 52 Week Low
- CSTL $15.45
- TRC $14.71
- 52 Week High
- CSTL $35.84
- TRC $19.82
- Technical
- Relative Strength Index (RSI)
- CSTL 56.09
- TRC 53.63
- Support Level
- CSTL $17.89
- TRC $16.06
- Resistance Level
- CSTL $19.38
- TRC $16.55
- Average True Range (ATR)
- CSTL 0.82
- TRC 0.36
- MACD
- CSTL 0.26
- TRC 0.04
- Stochastic Oscillator
- CSTL 77.46
- TRC 77.12
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About TRC Tejon Ranch Co
Tejon Ranch Co is a diversified real estate development and agribusiness company committed to responsibly using its land and resources to meet the housing, employment, and lifestyle needs of Californians and create value for its shareholders. It has five segments namely Real Estate - Commercial/Industrial, Real Estate - Resort/Residential, Mineral Resources, Farming, and Ranch Operations.